Background & Aims
Background: Peripheral neuropathy is the most common neurological toxicity induced by chemotherapy and can impact the quality of life and daily activities of patients, leading to sensory changes, mobility difficulties, risk of falls, and pain. Nurses monitor patients undergoing chemotherapy and collaborate in symptom management. Therefore, they must equip themselves to identify and manage risks associated with chemotherapy-induced peripheral neuropathy. Aim: To assess the prevalence and factors associated with chemotherapy-induced peripheral neuropathy and neuropathic pain in patients undergoing chemotherapy.
Methods
A multicenter cross-sectional study with data collection in three specialized oncology centers. Adult and elderly patients aged 18 or older undergoing chemotherapy from the fourth application cycle will be included. Participant assessment will be conducted through a guided interview using a sociodemographic and clinical form, the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool (CIPNAT), and the DN4 Questionnaire for neuropathic pain diagnosis. Data will be analyzed using descriptive and inferential statistics. The project will be submitted to the Research Ethics Committee of the University of São Paulo School of Nursing, with co-participation from the Cancer Institute of the State of São Paulo (ICESP), A.C. Camargo Cancer Center, and the National Cancer Institute (INCA). Data collection will begin after approval from the Ethics Committee of all participating institutions.
Results
Expected Results: This study is expected to contribute to the understanding of chemotherapy-induced peripheral neuropathy and chemotherapy-related neuropathic pain in our setting.
Conclusions
The findings may help establish more effective strategies for early identification and management of these conditions, preventing treatment interruption and complications.
References
BOUHASSIRA, D. et al. Comparison of pain syndromes associated with nervous or somatic lesions and development of a new neuropathic pain diagnostic questionnaire (DN4). Pain, [S.L.], v. 114, n. 1, p. 29-36, mar. 2005. Ovid Technologies (Wolters Kluwer Health). https://dx.doi.org/10.1016/j.pain.2004.12.010.
QUINTÃO, N. L. M; et al. Pharmacological Treatment of Chemotherapy-Induced Neuropathic Pain: ppar? agonists as a promising tool. Frontiers In Neuroscience, [S.L.], v. 13, p. 1-17, 28 ago. 2019.
TOFTHAGEN, C. S.; MCMILLAN, S. C.; KIP, K. E.. Development and Psychometric Evaluation of the Chemotherapy-Induced Peripheral Neuropathy Assessment Tool. Cancer Nursing, [S.L.], v. 34, n. 4, p. 10-20, jul. 2011.
WORLD HEALTH ORGANIZATION. Geneva. Available from: <https://www.who.int/cancer/en/>.
ZRAIK, I. M.; HEß-BUSCH, Y. Management von Nebenwirkungen der Chemotherapie und deren Langzeitfolgen. Der Urologe, [S.L.], v. 60, n. 7, p. 862-871, 29 jun. 2021.
YOON, S. Y; OH, J. Neuropathic cancer pain: prevalence, pathophysiology, and management. The Korean Journal Of Internal Medicine, [S.L.], v. 33, n. 6, p. 1058-1069, 1 nov. 2018. Korean Association of Internal Medicine. https://dx.doi.org/10.3904/kjim.2018.162
SANTOS, J. G. et.al. Translation to Portuguese and Validation of the Douleur Neuropathique 4 Questionnaire. The Journal Of Pain, [S.L.], v. 11, n. 5, p. 484-490, maio 2010. Elsevier BV. https://dx.doi.org/10.1016/j.jpain.2009.09.014.
Presenting Author
Ruan Nilton Rodrigues Melo
Poster Authors
Topics
- Epidemiology